About ViraTherapeutics GmbHViraTherapeutics GmbH is a biotech company based in Innsbruck, Tyrol, Austria. The company was formed as a spin-off of the Medical University of Innsbruck in April 2013.
ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed.
ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinical trials in cancer patients in 2018 at the earliest.
ViraTherapeutics is funded by JITU-Seedfinancing of the BMWFW executed by aws.
Founder: George Church
CEO: Shawn Marcell
Please click here for ViraTherapeutics's technology.
Please click here for ViraTherapeutics job opportunities.
5 articles with ViraTherapeutics GmbH
Boehringer Ingelheim announced earlier this week that Christopher Corsico was leaving the company, effective December 31. Today it was announced that Corsico will join GSK to take on the new role of senior vice president of development.
EMBL Ventures Portfolio Company, ViraTherapeutics Acquired by Boehringer Ingelheim in EUR 210 million (USD 245 million) Transaction
ViraTherapeutics sale marks third exit from EMBL Ventures’ current fund ETF II Heidelberg, Germany, 13th Sept
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
Boehringer Ingelheim exercises its option to acquire all shares of oncolytic virus company ViraTherapeutics
9/13/2018Heidelberg, Germany-based Boehringer Ingelheim has exercised its option to buy an EMBL Ventures portfolio company, ViraTherapeutics. This follows a collaboration and option deal inked between the two companies in August 2016.